CVRx (NASDAQ:CVRX) Announces Earnings Results

CVRx (NASDAQ:CVRX) posted its quarterly earnings results on Wednesday. The company reported ($0.49) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.01, FiscalAI reports. The company had revenue of $14.69 million for the quarter, compared to the consensus estimate of $14.16 million. CVRx had a negative return on equity of 79.31% and a negative net margin of 95.61%. CVRx updated its Q4 2025 guidance to EPS and its FY 2025 guidance to EPS.

CVRx Stock Performance

CVRX stock traded down $0.90 during mid-day trading on Friday, hitting $9.15. 114,357 shares of the company were exchanged, compared to its average volume of 290,693. The stock has a market capitalization of $239.19 million, a PE ratio of -4.31 and a beta of 1.28. The company has a current ratio of 11.99, a quick ratio of 10.78 and a debt-to-equity ratio of 0.85. CVRx has a 1-year low of $4.30 and a 1-year high of $18.55. The business has a 50 day simple moving average of $8.70 and a 200-day simple moving average of $7.52.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Geode Capital Management LLC increased its holdings in CVRx by 6.4% in the 2nd quarter. Geode Capital Management LLC now owns 382,437 shares of the company’s stock worth $2,249,000 after purchasing an additional 23,079 shares in the last quarter. XTX Topco Ltd bought a new stake in CVRx in the second quarter valued at approximately $155,000. Marshall Wace LLP raised its holdings in CVRx by 238.1% during the 2nd quarter. Marshall Wace LLP now owns 350,080 shares of the company’s stock worth $2,058,000 after purchasing an additional 246,548 shares during the last quarter. Cresset Asset Management LLC lifted its position in shares of CVRx by 3.5% in the 2nd quarter. Cresset Asset Management LLC now owns 53,542 shares of the company’s stock worth $315,000 after purchasing an additional 1,823 shares during the period. Finally, Bank of America Corp DE raised its stake in CVRx by 7.6% during the second quarter. Bank of America Corp DE now owns 89,049 shares of the company’s stock worth $524,000 after buying an additional 6,312 shares during the last quarter. Institutional investors own 75.27% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on CVRX. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of CVRx in a research note on Thursday, October 30th. Canaccord Genuity Group boosted their price target on CVRx from $9.00 to $11.00 and gave the company a “buy” rating in a report on Thursday. Finally, Cantor Fitzgerald increased their price objective on CVRx from $11.00 to $13.00 and gave the stock an “overweight” rating in a report on Thursday. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and two have given a Sell rating to the stock. According to data from MarketBeat, CVRx presently has a consensus rating of “Moderate Buy” and an average price target of $13.17.

About CVRx

CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.